NCT04967430 is a Phase 3 clinical trial of Peginterferon Lambda-1A in Sars-CoV2, sponsored by University Health Network, Toronto.

Who is sponsoring NCT04967430?

NCT04967430 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT04967430?

Interventions in NCT04967430: Peginterferon Lambda-1A, Placebo.

What condition does NCT04967430 study?

NCT04967430 studies Sars-CoV2, Covid19.

Is NCT04967430 still recruiting?

NCT04967430 is currently status unknown. Last updated 5 April 2022.

Last reviewed 2022-04-05 · How we verify

NCT04967430

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Status unknown Phase 3 Last updated 5 April 2022

What this trial tests

Phase 3 trial testing Peginterferon Lambda-1A in Sars-CoV2 in 763 participants. Status unknown.

Timeline

27 August 2021

Primary endpoint
21 March 2022

30 June 2022

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	763
Start date	27 August 2021
Primary completion	21 March 2022
Estimated completion	30 June 2022
Sites	1 location across Canada

Drugs / interventions tested

Peginterferon Lambda-1A — full drug profile →
Placebo

Conditions studied

Sars-CoV2 — all drugs for Sars-CoV2 →
Covid19 — all drugs for Covid19 →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Sars-CoV2 or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Interferon (IFN) lambda is one of the fundamental responses of the innate immune system. Peginterferon lambda is a long-acting form that has been studied extensively in human trials in viral hepatitis, confirming it safety and tolerability. It is particularly attractive for consideration in the use of acute respiratory illness due to the high expression of the lambda receptor in lung epithelia. We propose to evaluate peginterferon-lambda in ambulatory patients with mild to moderate COVID-19.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging principles of cytokine pharmacology and therapeutics.
Saxton RA, Glassman CR, Garcia KC. · · 2023 · cited 152× · PMID 36131080 · DOI 10.1038/s41573-022-00557-6
PEGylated therapeutics in the clinic.
Gao Y, Joshi M, Zhao Z, Mitragotri S. · · 2024 · cited 133× · PMID 38193121 · DOI 10.1002/btm2.10600
Engineering cytokine therapeutics.
Deckers J, Anbergen T, Hokke AM, de Dreu A, et al · · 2023 · cited 132× · PMID 37064653 · DOI 10.1038/s44222-023-00030-y
Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic.
Bian DJH, Sabri S, Abdulkarim BS. · · 2022 · cited 9× · PMID 35892857 · DOI 10.3390/cancers14153598
Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?
Brzoska J, von Eick H, Hündgen M. · · 2023 · cited 8× · PMID 37324124 · DOI 10.3389/fmed.2023.1198576
Current Landscape of IFN-λ: Induction, Inhibition, and Potential Clinical Applications to Treat Respiratory Viral Infections.
Martínez-Espinoza I, Guerrero-Plata A. · · 2023 · cited 6× · PMID 37071039 · DOI 10.4049/immunohorizons.2200010
Lessons from SARS‑CoV‑2 and its variants (Review).
Qin Z, Sun Y, Zhang J, Zhou L, et al · · 2022 · cited 6× · PMID 35730623 · DOI 10.3892/mmr.2022.12779
Yin and yang of interferons: lessons from the coronavirus disease 2019 (COVID-19) pandemic.
Svensson Akusjärvi S, Zanoni I. · · 2024 · cited 5× · PMID 38776716 · DOI 10.1016/j.coi.2024.102423

Verify or expand the search:

Other trials of Peginterferon Lambda-1A

Trials testing the same drug.

NCT04354259 — Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 · Phase 2 · completed
NCT02765802 — A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection · Phase 2 · completed

Other recruiting trials for Sars-CoV2

Currently open trials in the same condition.

NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04363853 — Tocilizumab Treatment in Patients With COVID-19 · Phase 2 · active not recruiting
NCT04424992 — The Natural History of Hospitalized COVID-19 Patients · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04967430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 5 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04967430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing